#China #Nanjing #HiCM-188 #HELP Therapeutics #China Resources Sanjiu

HELP Therapeutics and China Resources Sanjiu Form Strategic Alliance

HELP Therapeutics, a prominent name in regenerative medicine, has recently established a strategic partnership with China Resources Sanjiu Pharmaceutical Company. This collaboration aims to co-develop and commercialize HiCM-188, an innovative investigational cell therapy designed to address the growing challenge of advanced heart failure.

Addressing a Pressing Medical Need

Heart failure represents a severe health crisis worldwide, with its prevalence projected to soar at double-digit rates. In China alone, it is estimated that around 12 million adults suffer from this condition, leading to nearly 3 million new cases annually. Astonishingly, the five-year survival rates for heart failure patients resemble those of numerous aggressive malignancies. For individuals battling end-stage heart failure, heart transplantation remains the only validated treatment option. However, the stark reality is that fewer than 0.1% of patients receive a matching donor heart in time to save their lives. Consequently, new therapies such as cell therapy are being viewed as promising alternatives that could reshape care for this significant patient demographic.

HiCM-188: A Groundbreaking Therapy

HiCM-188 is noteworthy as the world's first iPSC-derived (induced pluripotent stem cell) regenerative therapy to secure IND (Investigational New Drug) clearance in both the United States and China. Currently, this promising treatment is undergoing Phase II clinical trials in China and Phase I/II trials in the United States, Singapore, and Thailand. Across more than five years of extensive follow-up studies, HiCM-188 has demonstrated a robust profile in terms of safety and efficacy, fueling excitement about its potential to transform patient outcomes.

Turning Hope into Action

Dr. Wang Jiaxian, the founder and CEO of HELP Therapeutics, remarked on the significance of this partnership. He expressed that the collaboration with China Resources Sanjiu is a considerable milestone for HELP Therapeutics. With a formidable clinical network and a commitment to innovation, China Resources Sanjiu is poised to expedite the accessibility of these crucial therapies for patients while positively influencing the growth trajectory of China’s cell therapy sector.

In agreement, Mr. Qiu Huawei, Chairman of China Resources Sanjiu, highlighted the potential of cell therapy as the future of life sciences. He noted that it could provide substantial therapeutic benefits for aging-related diseases and those resistant to standard treatments. With their subsidiary, Tasly Pharmaceuticals, already active in the MSC (Mesenchymal Stem Cells) cell therapy space, this partnership reflects their ongoing commitment to lead innovation in cell therapy.

Expert Endorsements

The collaboration garnered praise from Professor Junbo Ge, an academician of the Chinese Academy of Sciences, who views it as a groundbreaking development within China’s Cell and Gene Therapy (CGT) landscape. He emphasized that HELP Therapeutics' dedicated focus on treating heart failure directly addresses a critical clinical need, bridging a historically challenging gap between heart transplantation options and targeted myocardial repair therapies. According to Professor Ge, this partnership has the capability to redefine treatment paradigms for heart failure patients on a global scale.

About HELP Therapeutics

HELP Therapeutics stands at the forefront of regenerative medicine, committed to developing revolutionary therapies that tackle heart failure and other serious health issues. By leveraging its advanced iPSC platform and a strong clinical pipeline, HELP aims to significantly improve patient outcomes through innovative cell therapies.

In summary, the strategic partnership between HELP Therapeutics and China Resources Sanjiu represents a proactive step towards addressing the escalating heart failure crisis, empowering healthcare systems to meet the growing demands of patients with advanced cardiovascular conditions.